Accumulating evidence suggests that a subgroup of patients with COVID-19 might suffer
from severe complications, such as acute respiratory distress syndrome (ARDS) …

At more than 10 months after the first case of COVID-19 was documented, the understanding
of the pathogenesis of this viral illness is growing on a daily basis. A massive pro …

The outburst of inflammatory response and hypercoagulability are among the factors
contributing to increased mortality in severe COVID-19 cases. Pentoxifylline (PTX), a …

COVID-19 is a fatal, fast-spreading pandemic, and numerous attempts are being made
around the world to understand and manage the disease. COVID-19 patients may develop a …

Background: COVID-19, caused by SARS-CoV-2, is a potentially lethal, rapidly-expanding
pandemic and many efforts are being carried out worldwide to understand and control the …

We propose a new hypothesis that the established drug pentoxifylline deserves attention as
a potential repurposed therapeutic for COVID‐19. Pentoxifylline is an immunomodulator with …

The existing pandemic viral infection caused by severe acute respiratory syndrome
coronavirus type 2 (SARS-CoV-2) leads to coronavirus disease 2019 (Covid-19). SARS …

Pentoxifylline (PTX) is a phosphodiesterase inhibitor that increases cyclic adenosine
monophosphate levels, which in turn activate protein kinase, leading to a reduction in the …

Pentoxifylline (PTX) has broad-spectrum properties such as anti-inflammatory,
anticoagulant, and antiviral effects. The aim of this study was to evaluate the efficacy and …

In December 2019, a new coronavirus, named severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), emerged from China, causing pneumonia outbreaks first in …